Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Field study on the decrease of lipids using etofibrate]

J Schneider, W Haase, H Kaffarnik

    Fortschritte Der Medizin
    |May 6, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.

    Atherosclerosis·1999
    Same author

    [Alcohol, lipid metabolism and coronary heart disease].

    Herz·1996
    Same author

    Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.

    Journal of cardiovascular pharmacology·1996
    Same author

    [Oral contraceptive-induced pancreatitis in the hyperchylomicronemia syndrome].

    Deutsche medizinische Wochenschrift (1946)·1995
    Same author

    Influence of somatostatin to biochemical parameters in patients with primary hyperparathyroidism.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·1995
    Same author

    [Adrenomyeloneuropathy. A frequent cause of Addison's disease].

    Deutsche medizinische Wochenschrift (1946)·1994
    Same journal

    [More information--less pain. Procedure in pain following amputation of limbs. Brachial plexus injury and nerve root avulsion. Interview by Susanne Kammerer].

    Fortschritte der Medizin·1999
    Same journal

    [Galenic alternatives to unstable tocopherol acetate. "Smeared" or cheated?--Vitamin E in facial ointments].

    Fortschritte der Medizin·1999
    Same journal

    [Gene diagnosis in the hand of the physician].

    Fortschritte der Medizin·1999
    Same journal

    [Is non-toxic cancer therapy through biotechnology a possibility?].

    Fortschritte der Medizin·1999
    Same journal

    [Smoking withdrawal in practice and clinic].

    Fortschritte der Medizin·1999
    Same journal

    [The future of pancreas diagnosis. An exclusive training service of the Gastro-Ligue for dermatologists].

    Fortschritte der Medizin·1999
    See all related articles

    Etofibrat significantly reduced cholesterol and triglyceride levels in patients with hyperlipoproteinemia, with nearly 90% showing positive responses. This lipid-lowering drug demonstrated good tolerance and efficacy, even in patients previously treated with other agents.

    Area of Science:

    • Pharmacology
    • Clinical Medicine
    • Cardiovascular Disease

    Context:

    • Hyperlipoproteinemia is a significant risk factor for cardiovascular disease.
    • Effective lipid-lowering agents are crucial for managing cardiovascular health.
    • Previous treatments may have limitations or insufficient efficacy.

    Purpose:

    • To evaluate the efficacy and safety of Etofibrat in treating hyperlipoproteinemia.
    • To assess the lipid-lowering effects of Etofibrat over time.
    • To compare Etofibrat's performance with other lipid-lowering agents.

    Summary:

    • A field trial involving 4405 patients demonstrated Etofibrat's significant reduction in serum cholesterol and triglycerides within 3-8 weeks.
    • Nearly 90% of patients responded positively, with sustained lipid reduction in long-term use and good to very good tolerance.

    Related Experiment Videos

  • Etofibrat showed efficacy even in patients with prior unsuccessful treatments and exhibited favorable effects on liver enzymes (SGOT, SGPT, gamma-GT).

    • Impact:

    • Etofibrat offers a well-tolerated and effective therapeutic option for managing hyperlipoproteinemia.
    • The study suggests Etofibrat may have a favorable pharmacokinetic profile, potentially allowing for lower daily doses.
    • Findings support Etofibrat's role in improving lipid profiles and potentially reducing cardiovascular risk.